Therini Bio

Therini Bio is a private, San Francisco-based biotech founded in 2019, advancing a novel therapeutic platform targeting fibrin-mediated neuroinflammation. The company has a clinical-stage pipeline aimed at large markets with high unmet need, such as Alzheimer's disease and diabetic macular edema. It is led by an experienced team with deep expertise in neurology, ophthalmology, and drug development, and is backed by a top-tier syndicate of life science investors.

Platform developing biologics (antibodies) that selectively target toxic fibrin deposits to halt chronic innate immune activation and neuronal damage driven by vascular dysfunction.

In Alzheimer's, Therini competes with large pharma and biotechs focused on amyloid, tau, and other neuroinflammatory targets. In ophthalmology, it faces established anti-VEGF therapies and new entrants in the DME space. Its differentiation lies in its specific focus on fibrin as a root-cause driver of inflammation.